Suppr超能文献

COPD 和微量白蛋白尿:一项为期 12 年的随访研究。

COPD and microalbuminuria: a 12-year follow-up study.

机构信息

Health Trust Nord-Trøndelag, Dept of Internal Medicine, Levanger.

出版信息

Eur Respir J. 2014 Apr;43(4):1042-50. doi: 10.1183/09031936.00160213. Epub 2014 Jan 16.

Abstract

Chronic obstructive pulmonary disease (COPD), low lung function independent of diagnosis and markers of inflammation are all associated with increased morbidity and mortality. Microalbuminuria, reflecting endothelial dysfunction, could be a relevant inflammatory marker of potential systemic effects of COPD. We hypothesised that there was a positive association between microalbuminuria and mortality in individuals with COPD. We conducted a 12-year follow-up study of 3129 participants in the second survey of the Nord-Trøndelag Health Study (HUNT), Norway. At baseline, albuminuria was analysed in three urine samples and spirometry was performed. Among the participants, 136 had COPD and microalbuminuria, defined as a urinary albumin/creatinine ratio between 2.5 and 30.0 mg·mmol(-1). The main outcome measures were hazard ratio of all-cause mortality according to microalbuminuria. Compared to those with COPD without microalbuminuria, the adjusted hazard ratio for all-cause mortality in those with COPD and microalbuminuria was 1.54, 95% CI 1.16-2.04. This result was similar after excluding cardiovascular disease at baseline. Classifying COPD severity by Global Initiative for Chronic Obstructive Lung Disease, there was a positive association trend with increasing severity stages. Microalbuminuria is associated with all-cause mortality in individuals with COPD and could be a relevant tool in identification of patients with poor prognosis.

摘要

慢性阻塞性肺疾病(COPD)、肺功能降低而与诊断和炎症标志物无关,均与发病率和死亡率增加相关。反映内皮功能障碍的微量白蛋白尿可能是 COPD 潜在全身效应的相关炎症标志物。我们假设 COPD 患者的微量白蛋白尿与死亡率之间存在正相关。我们对挪威特隆赫姆第二健康调查(HUNT)的 3129 名参与者进行了为期 12 年的随访研究。在基线时,对三份尿液样本进行了尿白蛋白分析,并进行了肺功能检查。在参与者中,有 136 人患有 COPD 和微量白蛋白尿,定义为尿白蛋白/肌酐比值在 2.5 至 30.0mg·mmol(-1)之间。主要观察指标是根据微量白蛋白尿计算的全因死亡率的危害比。与无微量白蛋白尿的 COPD 患者相比,伴有微量白蛋白尿的 COPD 患者的全因死亡率调整危害比为 1.54,95%CI 为 1.16-2.04。在排除基线时的心血管疾病后,这一结果仍然相似。根据全球慢性阻塞性肺疾病倡议对 COPD 严重程度进行分类,随着严重程度阶段的增加,与死亡率呈正相关趋势。微量白蛋白尿与 COPD 患者的全因死亡率相关,可能是识别预后不良患者的相关工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验